Avidity Partners Management’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Avidity Partners Management’s Portfolio FUSN Stock Details FUSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-6,500,328	Closed	-$139M	–	107
2024 Q1	$139M	Hold	6,500,328	–	–	4.47%	2
2023 Q4	$62.5M	Buy	6,500,328 +718,478	+12%	+$3.49M	2.28%	12
2023 Q3	$15M	Buy	5,781,850 +81,850	+1%	+$262K	0.61%	57
2023 Q2	$26.6M	Hold	5,700,000	–	–	0.93%	44
2023 Q1	$21.5M	Buy	+5,700,000	New	+$22.4M	0.71%	44
2020 Q3	–	Sell	-164,554	Closed	-$2.88M	–	90
2020 Q2	$2.88M	Buy	+164,554	New	+$2.87M	0.18%	55

Avidity Partners Management's FUSN Position: Q2 2024 in Review

Avidity Partners Management sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q2 2024, closing a stake of 6,500,328 shares — an estimated $139M sold.

Avidity Partners Management first reported a position in FUSN in Q2 2020 and held it in 6 quarters. The position peaked at $139M in Q1 2024. 0 funds tracked by Wall St. Rank hold FUSN as of Q2 2024.

Avidity Partners Management reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q2 2024 after selling out during the quarter.
Avidity Partners Management sold 6,500,328 Fusion Pharmaceuticals Inc. Common Shares shares in Q2 2024, an estimated $139M.
Avidity Partners Management first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q2 2020 and held it in 6 quarters.
Avidity Partners Management's Fusion Pharmaceuticals Inc. Common Shares position peaked at $139M in Q1 2024.
0 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q2 2024.

Based on Avidity Partners Management's 13F filing for Q2 2024, filed 14 Aug 2024.